877397-70-1

Basic information

• Product Name: (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine
• Synonyms: (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine;3-[[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]oxy]-2-nitropyridine;3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-2-nitropyridine;Pyridine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-2-nitro-
• CAS NO: 877397-70-1
• Molecular Formula: C₁₃H₉Cl₂FN₂O₃
• Molecular Weight: 331
• Mol File: 877397-70-1.mol
• Article Data: 22

Chemical Properties

• Appearance: /
• Density: 1.474
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine(877397-70-1)
• EPA Substance Registry System: (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine(877397-70-1)

Safety Data

• Hazardous Substances Data: 877397-70-1(Hazardous Substances Data)

Usage

General Description

(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine is a chemical compound with the molecular formula C13H8Cl2FNO4. It is commonly used in the synthesis of various pharmaceuticals and agrochemicals. (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine is a potent inhibitor of the enzyme cyclin-dependent kinase 4 (CDK4), which is involved in the regulation of cell cycle. It is also a key intermediate in the production of certain nitro-containing compounds. The presence of nitro and halogen groups in its structure makes it a highly reactive and versatile molecule for use in organic synthesis. Overall, (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine serves as a valuable building block in the development of biologically active compounds and new drug candidates.

Upstream product

• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 
• 330156-50-8 (R)-1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol 
• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 15128-82-2 3-hydroxy-2-nitropyridine 
• 877399-98-9 C₉H₉Cl₂FO₃S 
• 54231-35-5 3-fuoro-2-nitropyridine 
• 877397-65-4 (S)‐1‐(2,6-dichloro-3-fluorophenyl)ethanol 

Downstream Products

• 877399-47-8 (R)-5-bromo-N,N-bis-(tert-butoxycarbonyl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridine-2-amine 
• 877399-48-9 (R)-N,N-bis(tert-butoxycarbonyl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine 

Relevant articles and documents

Novel pyridine derivatives having inhibition activity against SHIP2 and pharmaceutical compositions with the components

The present invention relates to a use as a pyridine derivative and/or a SHIP2 inhibitor. More specifically, the present invention relates to: a pyridine derivative of chemical formula I or pharmaceutically acceptable salt thereof; a method for manufacturing compounds thereof; and a pharmaceutical composition containing the compounds as active components. The pyridine derivative and the pharmaceutically acceptable salt thereof are useful as therapeutic agents for diseases related to SHIP2, such as Alzheimerandprime;s dementia, hypertension, cancer, diabetes, etc.COPYRIGHT KIPO 2020

Preparation method of deuterated crizotinib and derivatives thereof

The invention relates to a preparation method of deuterated crizotinib and derivatives thereof, and belongs to the technical field of synthesis of medical compounds. Four deuterated crizotinib with different configurations are synthesized, the influence of the deuterated position and different chirality of the deuterated crizotinib on the biological activity and the drug metabolism property of thecrizotinib is investigated, and the result shows that the deuterated crizotinib and the crizotinib have similar anti-cancer activity. Compared with a deuterated crizotinib raceme and crizotinib, thedeuterated crizotinib has certain physicochemical property advantages, has good anticancer application prospects, and provides a new compound for synthesis of novel antitumor drugs. The resolution ofthe racemate phenylethanol derivative is a key step for synthesizing the deuterated crizotinib, the ee value of the racemate phenylethanol derivative directly influences the ee value of a final product, and the resolution method has the characteristics of easiness in operation, low cost and the like.

PYRIDINE SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR CRYSTAL

The present invention discloses a crystal of citrate salt of pyridine-substituted 2-aminopyridine-based protein kinase inhibitors, in particular, to crystal of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4′-methoxy-6′-((S)-2-methylpiperazin-1-yl)-3,3′-bipyridin-6-amine citrate salt, a method for preparation thereof, a crystalline composition and a pharmaceutical composition comprising the crystal, and further discloses the use of crystals of citrate salt of the compound of Formula I in protein kinase-related diseases. The crystals of citrate salt according to the present invention are superior to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4′-methoxy-6′-((S)-2-methylpiperazin-1-yl)-3,3′-bipyridin-6-amine or other salts of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4′-methoxy-6′-((S)-2-methylpiperazin-1-yl)-3,3′-bipyridin-6-amine in at least one aspect of bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, and the like.